UNITED STATES OF AMERICA —Akebia Therapeutics has finalized a senior secured term loan arrangement valued at up to USD 140 million with Symbiotic Capital. The agreement includes an immediately funded initial tranche of USD 60 million, the proceeds of which were deployed to completely retire a prior USD 55 million credit facility held with BlackRock. The remaining USD 80 million is structured as a discretionary incremental tranche, subject to the lender’s future approval. The debt instrument carries a five-year maturity timeline, featuring an interest-only period for the first 60 months, with principal repayment due at term completion. The applicable interest rate is variable, set at the higher of the WSJ Prime rate plus 4.5 percent or a floor of 11.5 percent.
This financial restructuring is strategically significant for the biopharmaceutical sector, as it demonstrates a viable pathway for clinical-stage and commercial-stage companies to secure nondilutive capital amid restrictive equity markets. By replacing existing obligations with a longer-duration facility, the organization mitigates near-term liquidity risks and reaffirms its operational cash runway for a minimum of two years. This stability is critical for sustaining ongoing research and development initiatives without forcing unfavorable equity raises that would dilute existing shareholder value.
The transaction highlights evolving dynamics in healthcare credit markets, where specialized lending platforms are increasingly filling the financing gap left by traditional venture capital. Stakeholders across the nephrology and broader pharmaceutical industries will monitor this development as a benchmark for alternative debt structuring. It signals to institutional investors that revenue-generating biopharmaceutical firms with targeted therapeutic portfolios can access tailored credit solutions to bridge the capital-intensive gap between clinical development and broader market expansion.
Akebia Therapeutics is a Massachusetts-based biopharmaceutical organization established in 2007, specializing in the development and commercialization of therapies designed to improve outcomes for patients affected by kidney disease. Symbiotic Capital operates as a dedicated healthcare credit platform, leveraging extensive industry expertise to deliver structured lending solutions that fuel the growth of established medical enterprises on a global scale.